Mymetics Corp (MYMX)

[bow-tie]

Aldeyra Therapeutics
Severe COVID-19 is characterized by cytokine release syndrome, which may lead to respiratory compromise, often including the requirement for mechanical ventilation. In a preclinical model of cytokine storm, ADX-629 has demonstrated broad-based reductions across a variety of TH1, TH2, and TH17 inflammatory cytokines, while upregulating the key anti-inflammatory cytokine, IL-10.

Aldeyra previously announced that Phase 2a clinical trials of ADX-629 in psoriasis and atopic asthma are expected to initiate in the second half of 2020.

But not using Virosomes:

https://www.businesswire.com/news/home/20200520005228/en/Aldeyra-Therapeutics-Advance-ADX-1612-Investigational-New-HSP90